Clinical trial results showed an objective response rate of 75% (95% CI, 64-83), with 59% of patients having a complete response and 16% having a partial response. The Food and Drug Administration ...

Lunsumio VELO targets CD20 on lymphoma cells and lymphocytes, enhancing immune response against cancer cells. The subcutaneous version offers a one-minute administration, reducing clinic time and side ...

At the recent American Society of Hematology annual meeting, early data from the Mithic-FL1 Trial demonstrated impressive response rates with frontline mosunetuzumab (Lunsumio) in high-tumor-bulk ...

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options. The introduction of CD19 ...

Epkinly plus R2 significantly improved PFS and response rates in relapsed/refractory follicular lymphoma, reducing disease progression risk by 79%. The Epkinly regimen achieved a 95% objective ...

Epcoritamab plus rituximab/lenalidomide significantly improved PFS and ORR compared with rituximab/lenalidomide alone. The Food and Drug Administration (FDA) has approved Epkinly ® (epcoritamab-bysp), ...

The US Food and Drug Administration has granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics /Bristol Myers Squibb) for adults with relapsed or refractory follicular ...

“It's nice to have another option that we can discuss with patients,” said Yasmin H. Karimi, MD, University of Michigan, about epcoritamab’s label expansion for difficult-to-treat relapsed/refractory ...

In the treatment of relapsed or refractory follicular lymphoma (R/R FL), the addition of tafasitamab to a standard 2-drug combination of lenalidomide and rituximab (len+R) significantly improves ...

Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a malignancy where the first-generation drug ibrutinib (Imbruvica) failed. "When ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging ...